MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Adaptive Biotechnologies Corporation Total Assets 2011-2026 | ADPT
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Adaptive Biotechnologies Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 513 M | 539 M | 661 M | 857 M | 923 M | 1.12 B | 912 M | 333 M | 362 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 B | 333 M | 691 M |
Quarterly Total Assets Adaptive Biotechnologies Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 491 M | 497 M | 511 M | 539 M | 559 M | 585 M | 620 M | 661 M | 718 M | 765 M | 791 M | 857 M | 884 M | - | 858 M | 923 M | 993 M | 1.03 B | 1.07 B | 1.12 B | 1.12 B | 1.12 B | 1.12 B | 912 M | 912 M | 912 M | 912 M | 333 M | 333 M | 333 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.12 B | 333 M | 775 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B |  USA |
 |
Apellis Pharmaceuticals
APLS
|
1.08 B | $ 20.24 | -2.22 % | $ 2.55 B | USA |
 |
Aptorum Group Limited
APM
|
16.1 M | $ 0.82 | -2.95 % | $ 4.47 M | China |
 |
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M |  France |
 |
Axsome Therapeutics
AXSM
|
690 M | $ 165.96 | -0.25 % | $ 8.26 B | USA |
 |
AbCellera Biologics
ABCL
|
1.36 B | $ 3.74 | -2.23 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Burford Capital Limited
BUR
|
3.11 B | $ 8.49 | -2.75 % | $ 1.38 B | Britain |
 |
Codexis
CDXS
|
149 M | $ 0.97 | -4.87 % | $ 71.2 M | USA |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
1.1 B | $ 24.04 | 0.67 % | $ 2.94 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - |  Russia |
 |
Corvus Pharmaceuticals
CRVS
|
45.6 M | $ 17.32 | -3.19 % | $ 832 M | USA |
 |
Champions Oncology
CSBR
|
32.3 M | $ 5.96 | -1.81 % | $ 81.4 M | USA |
 |
Daré Bioscience
DARE
|
22.1 M | $ 1.58 | -1.87 % | $ 13.4 M | USA |
 |
DBV Technologies S.A.
DBVT
|
65.7 M | $ 21.89 | -5.85 % | $ 2.12 B | France |
 |
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
58.7 M | $ 25.75 | -4.13 % | $ 690 M | USA |
 |
Eton Pharmaceuticals
ETON
|
31.7 M | $ 17.52 | -3.47 % | $ 449 M | USA |
 |
Exelixis
EXEL
|
2.84 B | $ 40.72 | -0.76 % | $ 11.1 B | USA |
 |
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | Canada |
 |
Amicus Therapeutics
FOLD
|
950 M | $ 14.35 | -0.1 % | $ 4.43 B | USA |
 |
Galectin Therapeutics
GALT
|
17.5 M | $ 2.9 | -5.23 % | $ 181 M | USA |
 |
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | Canada |
 |
Galapagos NV
GLPG
|
4.14 B | $ 32.94 | -3.37 % | $ 2.69 B |  Belgium |
 |
Greenwich LifeSciences
GLSI
|
4.09 M | $ 27.32 | -0.27 % | $ 356 M | USA |
|
Galecto
GLTO
|
38.2 M | $ 29.84 | -0.7 % | $ 793 M |  Danmark |
 |
Genmab A/S
GMAB
|
21.1 B | $ 27.53 | -7.17 % | $ 17.6 B | Danmark |
 |
Gossamer Bio
GOSS
|
312 M | $ 0.46 | 8.47 % | $ 70.2 M | USA |
 |
GeoVax Labs
GOVX
|
9.28 M | $ 1.53 | -1.92 % | $ 2.78 M | USA |
 |
Grifols, S.A.
GRFS
|
21.4 B | $ 8.54 | -6.11 % | $ 6.83 B |  Spain |
 |
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | USA |
 |
Halozyme Therapeutics
HALO
|
2.53 B | $ 69.01 | -1.2 % | $ 8.27 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
314 M | $ 3.17 | -5.09 % | $ 1.13 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M |  Israel |
 |
Hoth Therapeutics
HOTH
|
7.71 M | $ 0.99 | -2.47 % | $ 6.31 M | USA |
 |
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
1.3 B | $ 28.49 | -2.57 % | $ 1.65 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.27 B | $ 28.56 | -1.18 % | $ 1.64 B | USA |
 |
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | USA |